Merk D - Search Results

1

Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.

Flesch D, Gabler M, Lill A, Gomez RC, Steri R, Schneider G, Stark H, Schubert-Zsilavecz M, Merk D. Flesch D, et al. Among authors: merk d. Bioorg Med Chem. 2015 Jul 1;23(13):3490-8. doi: 10.1016/j.bmc.2015.04.035. Epub 2015 Apr 18. Bioorg Med Chem. 2015. PMID: 25934227

2

Innovations in the treatment of cystic fibrosis: outriders for the treatment of diseases with other genetic defects?

Schubert-Zsilavecz M, Merk D. Schubert-Zsilavecz M, et al. Among authors: merk d. Future Med Chem. 2011 Dec;3(16):1969-70. doi: 10.4155/fmc.11.157. Future Med Chem. 2011. PMID: 22098344 No abstract available.

3

New hope or drawbacks: will chronic kidney disease be treatable with small molecules in the near future?

Merk D, Schubert-Zsilavecz M. Merk D, et al. Future Med Chem. 2012 Mar;4(3):269-71. doi: 10.4155/fmc.11.182. Future Med Chem. 2012. PMID: 22393934 No abstract available.

4

Nuclear receptors as pharmaceutical targets: rise of FXR and rebirth of PPAR?

Merk D, Schubert-Zsilavecz M. Merk D, et al. Future Med Chem. 2012 Apr;4(5):587-8. doi: 10.4155/fmc.12.8. Future Med Chem. 2012. PMID: 22458677 No abstract available.

5

Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.

Merk D, Steinhilber D, Schubert-Zsilavecz M. Merk D, et al. Future Med Chem. 2012 May;4(8):1015-36. doi: 10.4155/fmc.12.47. Future Med Chem. 2012. PMID: 22650242 Review.

6

Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present).

Lamers C, Schubert-Zsilavecz M, Merk D. Lamers C, et al. Among authors: merk d. Expert Opin Ther Pat. 2012 Jul;22(7):803-41. doi: 10.1517/13543776.2012.699042. Epub 2012 Jun 15. Expert Opin Ther Pat. 2012. PMID: 22697317 Review.

7

[Non-agonist inhibitors of Cdk5-dependent phosphorylation of PPAR as insulin sensitizers in the future?].

Merk D, Schubert-Zsilavecz M. Merk D, et al. Pharm Unserer Zeit. 2012 May;41(3):182-3. doi: 10.1002/pauz.201290044. Pharm Unserer Zeit. 2012. PMID: 22844662 German. No abstract available.

8

Novel strategies to control lipid metabolism: can the antisense drug mipomersen fulfill the unmet need?

Merk D, Schubert-Zsilavecz M. Merk D, et al. Future Med Chem. 2012 Sep;4(14):1773-5. doi: 10.4155/fmc.12.119. Future Med Chem. 2012. PMID: 23043473 No abstract available.

9

Novel prostaglandin receptor modulators: a patent review (2002 - 2012) - part I: non-EP receptor modulators.

Lamers C, Flesch D, Schubert-Zsilavecz M, Merk D. Lamers C, et al. Among authors: merk d. Expert Opin Ther Pat. 2013 Jan;23(1):47-77. doi: 10.1517/13543776.2013.736495. Epub 2012 Nov 14. Expert Opin Ther Pat. 2013. PMID: 23151189 Review.

10

Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012).

Flesch D, Merk D, Lamers C, Schubert-Zsilavecz M. Flesch D, et al. Among authors: merk d. Expert Opin Ther Pat. 2013 Feb;23(2):233-67. doi: 10.1517/13543776.2013.744822. Epub 2013 Jan 4. Expert Opin Ther Pat. 2013. PMID: 23289354 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

194 results

Search Page

Filters